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Abstract
Background: We previously described a potent recombinant HIV-1 neutralizing protein, sCD4-17b, composed of
soluble CD4 attached via a flexible polypeptide linker to an SCFv of the 17b human monoclonal antibody directed
against the highly conserved CD4-induced bridging sheet of gp120 involved in coreceptor binding. The sCD4
moiety of the bifunctional protein binds to gp120 on free virions, thereby enabling the 17b SCFv moiety to bind
and block the gp120/coreceptor interaction required for entry. The previous studies using the MAGI-CCR5 assay
system indicated that sCD4-17b (in concentrated cell culture medium, or partially purified) potently neutralized
several genetically diverse HIIV-1 primary isolates; however, at the concentrations tested it was ineffective against
several other strains despite the conservation of binding sites for both CD4 and 17b. To address this puzzle, we
designed variants of sCD4-17b with different linker lengths, and tested the neutralizing activities of the
immunoaffinity purified proteins over a broader concentration range against a large number of genetically diverse
HIV-1 primary isolates, using the TZM-bl Env pseudotype assay system. We also examined the sCD4-17b sensitivities
of isogenic viruses generated from different producer cell types.
Results: We observed that immunoaffinity purified sCD4-17b effectively neutralized HIV-1 pseudotypes, including
those from HIV-1 isolates previously found to be relatively insensitive in the MAGI-CCR5 assay. The potencies were
equivalent for the original construct and a variant with a longer linker, as observed with both pseudotype particles
and infectious virions; by contrast, a construct with a linker too short to enable simultaneous binding of the sCD4
and 17b SCFv moieties was much less effective. sCD4-17b displayed potent neutralizing activity against 100% of
nearly 4 dozen HIV-1 primary isolates from diverse genetic subtypes (clades A, B, C, D, F, and circulating
recombinant forms AE and AG). The neutralization breadth and potency were superior to what have been reported
for the broadly neutralizing monoclonal antibodies IgG b12, 2G12, 2F5, and 4E10. The activity of sCD4-17b was
found to be similar against isogenic virus particles from infectious molecular clones derived either directly from the
transfected producer cell line or after a single passage through PBMCs; this contrasted with the monoclonal
antibodies, which were less potent against the PMBC-passaged viruses.
Conclusions: The results highlight the extremely potent and broad neutralizing activity of sCD4-17b against
genetically diverse HIV-1 primary isolates. The bifunctional protein has potential applications for antiviral
approaches to combat HIV infection.
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The human immunodeficiency virus (HIV) envelope gly-
coprotein (Env) mediates virion entry into target cells by
orchestrating sequential binding of the gp120 subunit to
receptors on the target cell surface, first to CD4, then to
the coreceptor (chemokine receptor CCR5 or CXCR4);
receptor binding then activates the Env gp41 subunit to
promote direct fusion between the virion and plasma
membranes [1-3]. The binding sites for both CD4 and
coreceptor contain determinants that are highly con-
served, not only within the quasispecies present in the
infected individual, but also across the wide genetic
diversity of HIV-1 variants found globally. Env has
evolved a multilayered structural strategy to protect
these critical conserved elements, thereby allowing
chronic replication to continue in the face of a humoral
antibody response that might otherwise be neutralizing
[4-8]. Particular attention has been given to a “confor-
mational masking” mechanism [9] whereby the highly
conserved “bridging sheet” of gp120 [10,11], a critical
component of the coreceptor binding site [12,13], is hid-
den or unformed on free virions, and becomes exposed/
formed/stabilized only after gp120 undergoes major con-
formation changes induced by CD4 binding [9,14,15].
These structural complexities have profound implica-
tions for HIV neutralizationb ya n t i b o d y .T h ei m m u n e
system is capable of eliciting high titer antibody
responses against the conserved CD4-induced bridging
sheet, both during natural infection [16] and in response
to immunization, particularly with appropriately engi-
neered gp120 derivatives [17-19]. Several human mono-
clonal antibodies (MAbs) directed against the bridging
sheet have been derived from B cells of infected indivi-
duals [20-24]. These MAbs, of which 17b is an exten-
sively studied prototype, are broadly cross-reactive with
gp120 molecules from widely diverse HIV-1 primary iso-
lates. Indeed, the first X-ray crystallographic structures
of gp120 were solved for a trimolecular complex con-
taining a gp120 “core” bound to a soluble CD4 (sCD4)
construct containing the first 2 extracellular domains
and the 17b Fab [10,11]. While antibodies against the
bridging sheet bind avidly to gp120-CD4 complexes and
block their interaction with coreceptor [22,23,25,26],
they are weakly neutralizing for HIV-1 primary isolates
because the epitopes are poorly exposed or unformed/
unstable on the virion prior to its engagement with CD4
[22,27]. An additional layer of Env protection is afforded
by the steric hindrance when the virion is bound to
CD4 on the target cell surface; the narrow space
between the virion and cell membranes impairs access
of an intact IgG molecule to the CD4-induced bridging
sheet [28]. Thus a particularly tempting but vexing chal-
lenge arises, namely how to design a strategy whereby
an anti-bridging sheet antibody can access its highly
conserved epitope on the free virion prior to its engage-
ment with CD4 on the target cell, thus neutralizing
infectivity for genetically diverse HIV-1 variants.
We previously reported the design of a bifunctional
HIV-1 neutralizing protein that exploits the two-step
receptor interaction mechanism to circumvent the con-
formational masking and steric hindrance mechanisms
that impede antibody access to the conserved bridging
sheet on gp120 [29]. sCD4-17b is a recombinant single
chain protein consisting of the first 2 domains of human
CD4 attached by a flexible polypeptide linker to a single
chain variable region construct (SCFv) of the 17b MAb.
The sCD4 moiety binds to gp120 on free virions and
induces the 17b epitope; binding of the 17b SCFv moiety
then blocks coreceptor interaction, thereby neutralizing
infectivity. We reported that sCD4-17b potently neutra-
lized several HIV-1 primary isolates of approximately a
dozen tested; however, nearly half were resistant, despite
the highly conserved nature of both the CD4 and 17b
binding sites. We speculated on plausible reasons for the
disappointingly limited neutralization breadth, and pro-
posed several experimental approaches to test these
explanations and possibly resolve the problem.
In the present report, we expressed and purified
variant forms of sCD4-17b and employed a widely used
high throughput assay to measure neutralization of len-
tiviral particles pseudotyped with Envs from a large
number of genetically diverse HIV-1 primary isolates.
Our results are highly favorable, with potent neutraliza-
tion of virtually 100% of the nearly 4 dozen pseudotypes
tested. The neutralization breadth was considerably
greater than that reported for the well-characterized
broadly neutralizing MAbs IgG b12, 2G12, 2F5 and
4E10. Moreover, we found that sensitivity to sCD4-17b
was relatively independent of the cellular source from
which the virions were produced, unlike the above-men-
tioned MAbs whose efficacy was significantly influenced,
as previously reported by others [30]. These results
reinvigorate prospects for practical applications of
sCD4-17b in efforts to combat the HIV pandemic.
Methods
Design and expression of sCD4-17b variants and related
protein constructs
As previously described [29], sCD4-17b contains the
first two domains of human CD4 (residues 1-183)
attached by a flexible polypeptide linker (designated L1)
to an SCFv of the 17b human MAb (VH attached to VL
by the 5 amino acid linker G4S, designated L2). In the
original construct, the L1 linker contained 35 amino
acids (seven repeats of the G4S motif). The alternate
sCD4-17b variants described in the present study are
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acids in the L1 linker (in each case, composed of the
associated number of G4S repeats). The constructs
described here are sCD4-35-17b (as in [29]), sCD4-40-
17b, and sCD4-5-17b. To enhance expression and
subsequent purification, all variants contained the
N-terminal leader sequence of human Ig kappa light
chain, and a 9 amino acid C-terminal epitope tag
derived from the intracellular C-terminus of bovine rho-
dopsin (designated C9, with the following sequence:
TETSQVAPA) that is recognized by the rho 1D4 MAb
[31] (herein referred to as 1D4). Constructs representing
the individual moieties (sCD4 and 17b scFV) were also
prepared, each containing the same N-terminal leader
sequence and C-terminal C9 epitope tag.
The DNA constructs were cloned first by PCR using a
Topo TA vector (Invitrogen), then digested with SalI
and NotI and ligated into SalI and NotI sites in the plas-
mid vector VRC8400 pCMV/R (a generous donation of
G. Nabel, NIH Vaccine Research Center) containing the
enhanced human cytomegalovirus promoter CMV/R
[32]. Plasmids were transformed into E. coli One Shot
Top10 cells (Invitrogen) and grown under kanamycin
selection. DNA was prepared using a Plasmid Maxi Kit
(Qiagen). Proteins were expressed by transient transfec-
tion of re-adherent FreeSyle 293F cells (Invitrogen)
using Fugene (Roche) according to manufacturer’s
instructions. Briefly, each 162 cm
2 flask was seeded with
~4 × 10
6 cells in DMEM containing 10% FCS, 24 hr
prior to transfection. The morning of transfection
DMEM was removed and replaced with serum-free
FreeStyle Medium (Invitrogen). Transfection mixtures
were prepared containing 10 μg of plasmid DNA, 100 μl
Fugene in 800 μl FreeStyle Medium and incubated 30
min at room temperature. Cells were then transfected
using polypropylene tips to deliver the DNA to the
monolayer and incubated for 5 days at 37°C. Culture
supernatants were harvested and centrifuged at 3500
RPM for 10 minutes to remove cell debris. Supernatants
were concentrated 10× with filters (Millipore, 30 kDa
cutoff for sCD4-17b and 10 kDa cutoff for the sCD4
and 17b SCFv individual proteins), dialyzed against PBS
pH 7.4, and either used immediately for purification or
frozen and stored at -80°C until further use.
Protein purification and analysis
The various sCD4-17b variants (and the proteins repre-
senting the individual sCD4 and 17b SCFv moieties)
were purified from the 10× concentrated supernatants
using a single step immuno-affinity procedure based on
binding of the C9 epitope tag to the 1D4 MAb [33].
Briefly, CNBr-activated Sepharose 4B (GE Healthcare)
was prepared according to the manufacturer’si n s t r u c -
tions and washed in 1 mM HCl. 1D4 murine MAb
(anti-C9, purchased from Flintbox, University of British
Columbia) was coupled in batch to the activated Sephar-
ose 4B in 0.1 M NaHCO3 containing 0.5 M NaCl at a
concentration of 5-10 mg protein/ml medium. The mix-
ture was rotated end-over-end overnight at 4°C. Active
groups were blocked with 0.1 M Tris-HCl buffer, pH
8.0 for 2 hours, and the beads were washed in three
cycles of alternating pH, 0.1 M acetic acid/sodium acet-
ate, pH 4.0 containing 0.5 M NaCl and 0.1 M Tris-HCl,
pH 8.0 containing 0.5 M NaCl. Concentrated media
supernatants containing sCD4-17b proteins (50-100 μg/
ml media) were diluted in Immunoaffinity Buffer [100
mM (NH4)2SO4,2 0m MT r i sp H8 . 0 ,2 %g l y c e r o l ]a n d
then bound in batch to the Sepharose-1D4 overnight at
4°C. Approximately 5 ml of Sepharose-1D4 mixture
were then loaded onto single use columns (BioRAD)
and washed four times with 5 ml of Immunoaffinity
Buffer, followed by a fifth wash with 5 ml Immunoaffi-
nity Buffer supplemented with 500 mM MgCl2.B o u n d
protein was competitively eluted using five elutions with
5 ml Immunoaffinity Buffer-500 mM MgCL2 containing
250-500 μM C9 peptide (95-98% purity, American Pep-
tide Company). Alternatively in some cases, C9 peptide
elution was performed in conjunction with low pH
using two elutions with 250 μM C9 peptide in 100 mM
glycine HCL, pH 2.7; fractions were collected into tubes
containing equal volumes of Tris HCl pH 9.0 to neutra-
lize the eluates. The final material was concentrated in
BSA passivated filters (Millipore, as described above)
and dialyzed against PBS, pH 7.4. Protein concentrations
were determined by quantitative immunoblot analysis of
serial dilutions of protein samples using the Odyssey
Imager (Li-Cor Biosciences) compared to a 2-domain
sCD4 protein standard of known concentration (pro-
vided by S Leow, Upjohn). Preparations of purified
sCD4-17b ranging from ~10-25 mg/ml (corresponding
to ~200-500 μM) were stored at 4°C.
Proteins were analyzed by reducing SDS-PAGE com-
bined with Coomassie Blue staining or Western blot
analysis. For Western blots, proteins were resolved on
4-12% Bis-Tris gels (Invitrogen), then transferred to
PDVF membranes using the IBlot Gel Transfer System
(Invitrogen). Primary antibody [sheep polyclonal anti-
CD4, NIAID AIDS Research and Reference Reagent
Program (ARRRP)], 1:5000; or 1D4 murine anti-C9
MAb, 1:1000) was diluted in Odyssey Blocking Buffer
(Li-Cor Biosciences) and incubated on the blots for 1 hr
at room temperature with gentle shaking. After three
vigorous washes (PBS, pH 7.4 with 0.2% Tween 20,
Sigma), the blots were incubated with secondary anti-
body (anti-sheep or anti-mouse immunoglobulin,
IRDyes, Li-Cor Biosciences) diluted 1:1000 in Odyssey
Blocking Buffer and incubated in a light resistant con-
tainer for 45-60 min at room temperature. The blots
Lagenaur et al. Retrovirology 2010, 7:11
http://www.retrovirology.com/content/7/1/11
Page 3 of 13were given four vigorous washes in wash buffer and a
final wash in PBS. Proteins were visualized using the
Odyssey Imager (Li-Cor Biosciences).
HIV-1 particle preparation
Lentivirus particles pseudotyped with the indicated HIV-
1 Env were prepared as described [34]. Briefly, 293T
cells (human kidney fibroblast cell line) were cultured in
DMEM with 10% FCS and 0.0002% plasmocin. T225
flasks were seeded with 6 × 10
6 cells. The following day,
flasks were transfected with 30 μg backbone plasmid
DNA and 10 μg Env plasmid DNA, and 120 μlF u g e n e
reagent in 1.2 ml FreeStyle medium. The mixture was
incubated at room temperature for 30 min, then applied
to the cell monolayer with a polypropylene pipette tip.
The cells were incubated overnight at 37°C in 5% CO2,
after which the medium was removed and 35 ml of
fresh DMEM-10% was added. At 48 hrs post-transfec-
tion, the supernatant was removed and filtered through
a0 . 4 5μM filter (Millipore). The supernatant was then
divided into 1 ml aliquots and stored frozen at -80°C.
Assays were performed with samples that had been fro-
zen/thawed only a single time.
Expression plasmids encoding most of the Envs from
clades A, B, and C were obtained from ARRRP; vectors
are indicated in the corresponding data sheets. Expres-
sion plasmids for Envs from 92RW020 and DJ263.8
(both clade A) as well as YU2 and Ba-L (both clade B)
were kindly provided by John Mascola (Vaccine
Research Center, NIH). Functional pseudotype particles
were generously donated by Vicky Polonis (Walter Reed
Army Institute of Research) and Sodsai Tovanabutra
(Henry M. Jackson Foundation) for some clade A Envs
as well as for Envs from clade D and the circulating
recombinant forms AE and AG (see Figure Legends).
For isolates 91US054 (clade B), 93IN905 (clade C), and
93BR029 (clade F), the Env genes were amplified by
PCR from PBMC cultures infected with the correspond-
i n gp r i m a r yi s o l a t e s( o b t a i n e df r o mA R R R P )u s i n gc o n -
served primers; the products were cloned first into a
TOPO TA vector (Invitrogen), then into VRC8400
pCMV/R (Not1 and Sal1 sites) to generate pseudotypes
as described above.
A series of experiments was performed with virus
particles derived from infectious molecular clones
(IMCs) from the BL01 and 89.6 isolates (both clade B).
For each, two types of particles (generously donated by
John Mascola and Mark Louder, Vaccine Research
Center, NIH) were employed: particles derived directly
from 293T cells transfected with the corresponding
plasmids, and particles derived by single passage of the
293T-derived viruses through mitogen-activated
PBMCs [30].
HIV-1 neutralization assays
The major neutralization assay employed herein was
analysis of HIV-1 Env pseudotype infection of TZM-bl
(JC53bl-13) cells [34]. This single cycle assay involves
measurement of luciferase activity in lysates of cells con-
t a i n i n gt h ef i r e f l yl u c i f e r a s eg e n el i n k e dt ot h eH I V - 1
LTR, dependent on entry of the pseudovirus particle.
Briefly, serial dilutions of the indicated agents were
made in PBS pH 7.4 in a 96 well plate, pseudovirus par-
ticles were then added to the agents and incubated for
30 min. TZM-bl cells were trypsinized and added to
each well, and the plates were incubated for 48 hrs at
37°C in 5% CO2. The cells were then lysed with Bright-
Glo Luciferase reagent (Promega) and luciferase activity
was measured using the Clarity luminometer (Biotek).
In the case of “live virus”, assays were performed in the
same manner except that the cells were lysed with cell
culture lysis buffer (Promega), prior to addition of
Bright-Glo reagent. All pseudotype preparations were
titered by measuring luciferase activity obtained with
serial dilutions of the stock preparation. Neutralization
experiments were performed with viral inputs of 50-200
TCID50 based on the cytopathic effects of particular
pseudotypes. IC50 values were determined with Prism 5
(GraphPad Software): nonlinear regression (curve fit);
log(inhibitor) versus response - variable slope (four
parameters); least squares (ordinary fit); unknowns inter-
polated from standard curve (95% confidence interval).
Activities are expressed as direct measurement of Rela-
tive Luminescence Units (RLU), or in some cases as %
of the designated control.
A small number of experiments were performed using
the MAGI-CCR5 assay [35] as previously described [29].
Briefly, 20 μl virus dilutions (expected to generate
approximately 200 blue cells per 10
4 MAGI-CCR5 cells)
were preincubated with 30 μl serial dilutions (in PBS,
pH 7.4) of sCD4-17b protein for 30 min at 37°C; 20 μg/
ml final concentration of DEAE-dextran was then added
to this mix and the contents were transferred to indivi-
dual wells of a 96-well plate containing the MAGI-
C C R 5c e l l s .A f t e r2h o u r s ,1 5 0μl of DMEM-10% FCS
was added to each well and the plate was incubated for
48 hours before fixing and staining the cells for micro-
scopic counting of blue nuclei.
Results
Our previous studies [29] analyzed a single sCD4-17b
c o n s t r u c tp r o d u c e di nm o d e s tq u a n t i t i e sa n da s s a y e d
mainly in the context of concentrated conditioned med-
ium containing the secreted protein. The neutralization
assay employed infectious HIV-1 virions from several pri-
mary isolates, using the MAGI-CCR5 system based on
microscopic visualization and counting of infected cells
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[35,36]. To expand upon these initial studies, in the pre-
sent report, we employed an efficient mammalian transi-
ent transfection system to produce mg quantities of
several sCD4-17b variant constructs and related proteins,
coupled with single-step immunoaffinity purification. For
HIV-1 neutralization, we used the single round TZM-bl/
Env pseudotype assay method, in which the firefly lucifer-
ase gene linked to the HIV-1 LTR is activated upon vir-
ion entry [34]. This high throughput system has many
desirable features for neutralization assays, and has been
adopted as a major component for evaluating plasma
antibodies generated during natural infection and vaccine
trials [37,38], as well for characterizing the breadth of
neutralization by various MAbs [39-41].
Expression and purification of secreted sCD4-17b variants
and related proteins
We previously speculated that a possible explanation for
the observed limited breadth of the original sCD4-17b
construct was that for some Envs, the flexible L1 linker
connecting the sCD4 and 17b SCFv moieties might have
been insufficiently long to enable simultaneous binding
of both components to the same gp120 subunit; differ-
ences in the size and conformation of variable loops
(which were not present in the gp120 core used for
X-ray crystallographic structure determinations) as well
as possible differences in orientation of the binding sites
for CD4 and 17b were offered as possible contributing
factors [29]. To extend the earlier studies, we designed
sCD4-17b variants with different L1 linker lengths. The
proteins are designated herein with a number represent-
ing the total number of amino acid residues in the L1
linker (composed of repeats of the G4S motif). Based on
the reported X-ray crystallographic analyses of ternary
complexes containing gp120 core proteins bound to 2
domain sCD4 and the 17b Fab [10,11], the flexible L1
linker connecting the sCD4 and 17b SCFv moieties
must span an atomic distance of 60 Å. Our previous
studies [29] were performed with a construct with an L1
linker consisting of 7 G4S repeats (herein designated
sCD4-35-17b); this length was predicted to be suffi-
ciently long to allow simultaneous binding of both moi-
eties to a single gp120 subunit. In the present study, we
wished to test whether a construct with a longer linker
(sCD4-40-17b) could overcome the previously observed
limited breadth; as a negative control, we also produced
a construct with an L1 linker predicted to be far too
short to allow simultaneous binding (sCD4-5-17b).
The sCD4-17b variants, as well proteins representing
the corresponding individual sCD4 and 17b SCFv moi-
eties, are depicted in Fig. 1A. In all cases the constructs
were engineered with an N-terminal Ig kappa secretion
leader sequence (in place of the native CD4 leader
sequence) as well as a C-terminal C9 epitope tag
(in place of the previous 6-his tag) for single-step immu-
noaffinity purification from concentrated cell culture
supernatants using the 1D4 MAb conjugated to Sephar-
ose 4B beads. These two modifications were found to
increase by several fold the amounts of the engineered
proteins secreted into the medium (data not shown).
We employed an efficient mammalian expression system
involving transient transfection of 293F cells with plas-
mids containing an enhanced human cytomegalovirus
promoter. The amounts of sCD4-17b secreted into the
culture supernatants typically ranged between 5-8 μg/ml.
An example of immunoaffinity purification is shown
for the sCD4-40-17b protein (Fig. 1B). Coomassie blue
staining of reducing SDS-PAGE gels demonstrated that
the expressed protein was only a minor component in
the initial concentrated supernatant loaded onto the
1D4-Sepharose beads; it was the major single band in the
first C9 peptide eluate fraction (E1), with mobility consis-
tent with the expected 51 kDa. Immunoblot analysis (not
shown) indicated that only minimal amounts of the pro-
tein were detected in the flow through and wash frac-
tions, confirming the efficiency of this single-step
immunoaffinity purification system. The other sCD4-17b
variants and the corresponding proteins representing the
individual moieties were expressed and purified in similar
fashion. Immunoblot analysis (Fig. 1C) verified that each
purified protein migrated on reducing SDS-PAGE gels at
the corresponding expected mobility. We also observed
that purified sCD4-17b proteins migrated on non-redu-
cing gels as monomers (~51 kDa, data not shown).
Effects of the L1 linker length of sCD4-17b and HIV-1
virus particle types on neutralization
One major focus was to test whether lengthening the L1
linker might convey greater neutralization breadth to
sCD4-17b. Fig. 2A shows results in the TZM-bl assay
with pseudotype virus of the primary isolate US054
(clade B), which was insensitive to sCD4-35-17b in the
previously reported MAGI-CCR5 assay [29]. Perhaps sur-
prisingly, both the original sCD4-35-17b and the new
variant sCD4-40-17b neutralized effectively and with
equivalent potencies (IC50 = 11 nM for each). As a nega-
tive control, no neutralizing activity was observed against
pseudotype particles bearing the envelope glycoprotein of
amphotropic murine leukemia virus (data not shown).
Since the previous MAGI-CCR5 assays demonstrating
sCD4-17b resistance of several HIV-1 isolates were
performed with infectious virus rather than Env pseudo-
types [29], we compared both particle types in the
TZM-bl assay, again examining the 91US054 primary
isolate. As shown in Fig. 2A, sCD4-40-17b neutralized
infectious virus with potency (IC50 = 22 nM) similar to
that for pseudotyped particles. Additional experiments
Lagenaur et al. Retrovirology 2010, 7:11
http://www.retrovirology.com/content/7/1/11
Page 5 of 13Figure 1 Design and purification of sCD4-17b constructs and related proteins. A) Schematic representation of three sCD4-17b constructs
with different L1 linkers, with the total number of L1 amino acids indicated in the construct name (in each case consisting of the appropriate
number of repeats of the G4S motif). Also shown are the constructs representing the individual components sCD4 and 17b SCFv. All constructs
include the Ig kappa light chain leader sequence at the amino terminus, and the C9 epitope tag at the carboxy terminus. B) Immunoaffinity
purification of sCD4-40-17b, as analyzed by Coomassie Blue staining of reducing SDS-PAGE gels (10 μl per lane for each sample). In this example,
C9 peptide elution was performed in conjunction with low pH. The fractions analyzed were the initial concentrated media supernatant (load),
flow-through (FT), the 5 wash fractions (W1-W5) and the two elution fractions (E1, E2). Numbers on the left indicate molecular weight markers
(kDa). C) Western blot analysis of purified preparations of the indicated sCD4-17b proteins as well as the 17b SCFv and sCD4 proteins (10 μl per
lane for each sample). The 1D4 MAb directed against the C-terminal tag on each protein was used for detection.
Figure 2 HIV-1 neutralization of various isolates by different sCD4-17b constructs and related proteins. Assays were performed using the
TZM-bl system or where indicated, with the MAGI-CCR5 system. Dose-response analyses were performed with the indicated proteins and HIV-1
Env pseudotypes or infectious virus, as indicated by the symbols above the graphs and the names within the graphs. Each point represents the
mean of duplicate samples; error bars indicate SD. A) Comparison of the potencies of sCD4-35-17b and sCD4-40-17b against the 91US054
pseudotype and infectious virus. In the TZM-bl system, the IC50 values against the pseudotype were 11 nM for both sCD4-35-17b and sCD4-40-
17b; the value against the infectious virus was 22 nM for sCD4-40-17b. In the MAGI-CCR5 system, the IC50 value against the infectious virus was
30 nM. B) Comparison of the effects against the indicated Env pseudotypes of sCD4-40-17b, sCD4-5-17b (shorter linker) and proteins
representing individual moieties (sCD4 alone, or in combination with 17b SCFv). The IC50 values for sCD4-40-17b were 12.3 nM against
CAAN5342.A2, 9.8 nM against RW020, and 0.8 nM against YU2; the value for sCD4-5-17b against YU2 was 16.5 nM.
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assay indicated neutralization of several other primary
isolates previously found to be resistant in the MAGI-
CCR5 assay (93IN905, clade C; 93TH073, clade E;
93BR029, clade F) [29], with indistinguishable potencies
for sCD4-35-17b and sCD4-40-17b (data not shown).
We also examined whether features of the MAGI-CCR5
assay might be responsible for the previously reported
resistance of some HIV-1 primary isolates to sCD4-17b.
In the present study, the highest concentration (92 nM)
of affinity purified sCD4-17b protein used was ~3-fold
higher than the maximum concentration (32 nM) of
unpurified protein used in our earlier report. As shown
in Fig. 2A, sCD4-40-17b effectively neutralized infec-
tious virus of the US054 strain in the MAGI-CCR5
assay, albeit with a somewhat weaker potency (IC50 =3 0
nM) compared to the TZM-bl assay. We conclude that
the previously described insensitivity of some HIV-1 pri-
mary isolates to sCD4-17b was likely due to a combina-
tion of factors including insufficient concentrations of
the inhibitor and use of unpurified protein, rather than
to an insufficiently long L1 linker or to the use of infec-
tious virus in the previous study. Additional experiments
(see below) confirm the sCD4-17b sensitivity of infec-
tious virus particles from other HIV-1 isolates.
Very different results were obtained with sCD4-5-17b,
whose LI linker (a single G4S motif) is predicted to be
too short to enable simultaneous binding of the sCD4
and 17b SCFv moieties to a single gp120 subunit. Fig.
2B shows that for the primary isolates CAAN (clade B)
and 92RW020 (clade A), the IC50 values for sCD4-40-
1 7 bw e r ei nt h er a n g eo f1 0n M ,b u tn e g l i g i b l ei n h i b i -
tion occurred over the same concentration range with
sCD4-5-17b or with sCD4 alone or in combination with
equimolar concentrations of unlinked17b SCFv. When
even more sensitive isolates were examined, a more
subtle distinction emerged, as shown for the YU2 pri-
mary isolate (clade B). Very potent neutralization
occurred with sCD4-40-17b (IC50 0.8 nM), whereas no
inhibition was observed over the same concentration
range with sCD4, alone or in combination with unlinked
17bSCFv; however sCD4-5-17b neutralized, albeit with a
20-fold weaker potency (IC50 16.5 nM) compared to
sCD4-40-17b. Similar findings were observed with sev-
eral other highly sensitive isolates (e.g. 93IN905, Clade
C primary isolate, data not shown). The experiments
presented in the following sections were performed with
sCD4-40-17b.
Extremely broad and potent activity of sCD4-17b against
Env pseudotypes from genetically diverse primary
isolates
Genetically diverse HIV-1 isolates from different geo-
graphic regions worldwide share the requirement for
both CD4 and coreceptor (CCR5 and/or CXCR4) as tar-
get cell receptors for virus entry. The 17b epitope on
the bridging sheet component of the gp120 coreceptor
binding site has been shown to be highly conserved on
most/all HIV-1 strains examined [1,4,20,42], leading us
to predict that the neutralizing activity of sCD4-17b
should be extremely broad. Fig. 3 shows that this is
indeed the case, based on analysis of nearly 4 dozen
pseudotypes bearing Envs from each of the major
g e n e t i cs u b t y p e sr e p r e s e n t i n gc l a d e sA ,B ,C ,D ,F ,a n d
the circulating recombinant forms CRF01_AE and
CRF01AG. Based on categorization of potency pre-
viously employed by other groups assessing sensitivities
of Env pseudotypes to specific MAbs in the TZM-bl
assay [39-41] [also V. Polonis and S. Tovanabutra,
personal communication], virtually every one of the
pseudotypes examined was neutralized by sCD4-40-17b;
in fact nearly all IC50 values were in the ≤ 1 μg/ml or
>1-5 μg/ml categories, with only 3 in the >5-25 μg/ml
category (actually <10 μg/ml). Of particular note, each
of the newly tested isolates previously described as
sCD4-17b-insensitive in the MAGI-CCR5 assay [29]
(91US054, 93IN905, and 93BR029) was extremely
sensitive (IC50 ≤ 1 μg/ml).
This breadth is particularly impressive when compared
with sensitivities to the well-characterized broadly neu-
tralizing MAbs IgG b12, 2G12, 2F5 and 4E10. Fig. 4
shows such comparisons for the subset of pseudotypes
from Fig. 3 that have been analyzed in detail by others
for sensitivity to these MAbs; these include 9 from clade
A [41] [also V. Polonis and S. Tovanabutra, personal
communication], 12 each from clade B [39]) and clade C
[40] (both sets selected as reference panels for vaccine
evaluation), 3 from clade D and 3 from recombinant
clades CRF01_AE and CRF01AG (V. Polonis and S.
Tovanabutra, personal communication). The pie graphs
in Fig. 4 highlight the significantly greater breadth across
all clades of sCD4-40-17b compared to the activities of
each of these broadly neutralizing MAbs, all of which
were ineffective against multiple isolates from several
clades (based on data from others, and confirmed by us
in a limited number of cases, data not shown).
Neutralization of HIV-1 by sCD4-17b: independence from
cellular source of virion particles
The neutralization sensitivity of HIV-1 can depend
strongly on the cell type from which the virus particles
are produced. A particularly clear demonstration of this
involved analyses of IMCs from which virions were gen-
erated directly from plasmid-transfected 293T cells ver-
s u sa f t e ras i n g l ep a s s a g eo ft h e2 9 3 T - d e r i v e dv i r i o n s
through mitogen-stimulated PBMCs. Despite verification
of complete Env sequence identity between the matched
pairs of virions, the broadly neutralizing MAbs were
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Page 7 of 13Figure 3 Breadth of sCD4-40-17b activity against pseudotypes from genetically diverse HIV-1 primary isolates. Nearly all entries are
primary isolates for which the Env sequences were originally obtained by direct cloning from infected tissue; the exceptions are the laboratory-
adapted Ba-L, and 89.6 strains. The IC50 values (μg/ml) represent the mean of multiple independent assays (+/- SEM) (3-5 replicate assays in most
cases, 2 in a few instances). The values are color coded according to the IC50 ranges as indicated at the top of the figure, with
red<orange<yellow<white. Note that none of the IC50 values are in the white range (least potent). The superscript letters indicate the references
describing the individual isolates, as follows:
a[41], clade A;
b[39], clade B, tier 2 reference panel;
c[40], clade C reference panel;
d [V. Polonis and S.
Tovanabutra, personal communication], clades A, D, AE and AG. Further details on various features of these isolates can be found in these cited
references. ** Indicates isolates previously found to be insensitive to sCD4-17b in the MAGI-CCR5 assay using infectious virus [29].
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Page 8 of 13found to be significantly less potent against the PBMC-
derived virions compared to their cell line-derived coun-
terparts [30]. We assessed the activity of sCD4-40-17b
against matched pairs of 293-derived vs. PBMC-single
passaged virions; the activities of four broadly neutraliz-
ing MAbs were tested for comparison. Fig. 5 shows
results with IMCs from two distinct clade B isolates,
BL01 and 89.6; the results are expressed as the IC50
ratios of PBMC-derived versus 293 cell-derived virions.
While our results verified the previous report [30] that
PBMC-passage virions were considerably less sensitive
than their 293-derived counterparts to neutralization by
the MAbs, we found that they were comparably
sensitive to sCD4-40-17b. Sensitivity to sCD4 was also
independent of the cellular source of the virions, consis-
tent with previously reported findings [30].
Discussion
The data presented herein confirm and extend our pre-
vious conclusion [29] that the neutralizing potency of
sCD4-17b derives from the ability of both moieties on a
single bifunctional molecule to associate simultaneously
with their corresponding binding sites on a single gp120
subunit. Variants of the protein with sufficiently long L1
linkers, i.e. the original sCD4-35-17b and the newly
described sCD4-40-17b displayed potency much greater
Figure 4 Comparison of neutralization breadth of sCD4-40-17b with broadly neutralizing monoclonal antibodies. Each pie graph shows
the fraction of isolates within each IC50 range for each agent tested against isolates from the indicated clades. The color-coding for IC50 ranges
(indicated at the top of the Figure) is the same as in Figure 3, with red<orange<yellow<white. Note that whereas for sCD4-40-17b none of the
clades had isolates with IC50 values in the white range (least potent), each of the MAbs had some or all isolates with IC50 values in the white
range for at least some clades; thus when the total isolates where evaluated for “% neutralized”, the value was 100 for sCD4-40-17b but
considerably less for the MAbs. The pie graphs are based on the indicated number of isolates (#) in each clade, which are the ones designated
in Figure 3 with superscript letters. The sCD4-40-17b results are based on the data in Fig. 3; the MAb results are based on findings by others as
follows: clade A, 6 isolates [41], 3 isolates [V. Polonis and S. Tovanabutra, personal communication]; clade B, all 12 isolates (reference panel clade
B) [39]; clade C, all 12 isolates (reference panel clade C) [40]; all 3 clade D isolates [V. Polonis and S. Tovanabutra, personal communication]; all 3
clade AE and AG isolates [V. Polonis and S. Tovanabutra, personal communication].
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Page 9 of 13than either sCD4 alone, or in equimolar amounts with
unlinked 17b SCFV. Preliminary results indicated that a
construct containing an L1 linker of 55 amino acids (11
G4S repeats) was comparably effective (data not shown).
By contrast, sCD4-5-17b, which contains an L1 linker too
short to allow simultaneous binding of the sCD4 and 17b
moieties, had a much weaker potency. However when
tested against strains that were highly sensitive to sCD4-
17b, sCD4-5-17b proved significantly more effective than
the mixture of unlinked sCD4 plus 17b SCFv. A plausible
explanation is that while sCD4-5-17b was incapable of
mediating simultaneous binding of both components to
the same gp120 subunit, reversible binding of molecules
via the sCD4 portion effectively increased the local con-
centration of 17b SCFv in the vicinity of Env, where it
could bind to gp120 subunits that had been induced by
sCD4 moieties on separate molecules of the chimeric
protein. Thus bifunctional binding molecules can poten-
tially display enhanced activities even when the two bind-
ing moieties are incapable of interacting simultaneously
with a single target molecule.
The exceptional breadth displayed by sCD4-17b (neu-
tralization of 100% of isolates tested from genetically
diverse HIV-1 subtypes) confirms our original expecta-
tion, based on the requirement for CD4 binding
amongst all natural HIV variants coupled with the high
conservation of the bridging sheet due to its critical role
in coreceptor binding of HIV-1 (and HIV-2 as well
[16]). The breadth exceeded by a considerable margin
those of the well-characterized broadly neutralizing
MAbs IgG b12, 2G12, 2F5 and 4E10 tested against the
same HIV-1 isolates [39,40,43] (also V. Polonis and S.
Tovanabutra, personal communication). Of interest in
this regard is the recent report of 2 new human gp120-
targeted MAbs, PG9 and PG16, that neutralize a large
fraction (79% and 73%, respectively) of Env pseudotypes
from a genetically diverse panel of primary HIV-1 iso-
lates (IC50 values ranging from 0.001 to 50 μg/ml); of
the 162 pseudotypes examined, only 32 were resistant to
both MAbs (IC50 >50 μg/ml) [44]. In the present study,
1 of these PG9/PG16-resistant isolates was tested
against sCD4-17b and was found to be highly sensitive
(QH0692.42, Clade B, IC50 =0 . 6 6μg/ml, Fig. 3). It will
be most interesting to test the sCD4-17b sensitivities of
other strains resistant to these newly described MAbs.
Our previous observation of limited breadth in the
MAGI-CCR5 system was not due to the requirement of
a longer L1 linker for some strains, as we previously
speculated. Nor was it associated with the use of infec-
tious virus in that system, since the TZM-bl assay
demonstrated sCD4-17b sensitivity for infectious virus
from several isolates (Fig. 2A, Fig. 5); where tested, the
potency was comparable to that observed with the cor-
responding Env pseudotyped particles (Fig. 2A). Retest-
ing one of the previously described resistant isolates,
namely 91US054, in the MAGI-CCR5 assay suggested
that the limitation of neutralization breadth in our ear-
lier study might have resulted from insufficient concen-
tration of sCD4-17b (unpurified or partially purified),
coupled with the higher virus input volume required in
the MAGI-CCR5 assay compared to the TZM-bl assay
(20 μlv e r s u s5μl, respectively). We believe the present
findings of extremely broad neutralization activity of
sCD4-17b in the commonly used TZM-bl assay override
Figure 5 HIV-1 sensitivity to sCD4-40-17b: independence from cellular source of virions. IMCs from strains BL01 and 89.6 were used to
generate virus particles directly from transfected 293T cells; a second set of viruses was generated by single passage of the 293T-derived
particles in PBMCs [30]. Both sets of particles (directly provided to us by M. Louder and J. Mascola) were analyzed for sensitivity to the agents
shown. The results are plotted as the IC50 ratios of the PBMC-passaged to the 293T-derived virus particles. In each graph, the dotted line
indicates a ratio of 1 (i.e., equal potency against each type of virus particle).
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Page 10 of 13the limitations noted in our previous report, which were
most likely due to the specific conditions associated
with those experiments rather than to inherent proper-
ties of the sCD4-17b protein or the Env glycoproteins
that it targets.
The HIV-1 IMC experiments demonstrated a marked
contrast between sCD4-17b and neutralizing antibodies
with respect to the influence of the cellular source from
which the virus particles were derived. The potency of
sCD4-40-17b was equivalent against virions isolated
directly from the transfected producer cell line and pro-
geny virions obtained after single passage through
PBMCs (Fig. 5). By contrast, the PBMC-passaged virions
were significantly less sensitive to the broadly neutraliz-
ing MAbs, as previously shown by the group that pro-
vided the IMCs for our experiments; importantly, they
also demonstrated the absence of any sequence change
in Env after PBMC passage [30]. In that earlier report,
several possible explanations were offered for the
reduced antibody susceptibility of PBMC-passaged
viruses compared to their cell line-derived counterparts,
including higher levels of Env on virions from PBMCs,
differential incorporation of host cell factors such as
adhesion proteins during virus assembly in PBMCs, and
producer cell-dependent biochemical differences in the
gp160, such as differential glycosylation. In our opinion,
the first two mechanisms might be expected to result in
neutralization differences that are similar for various
classes of Env-blocking agents, and thus would not read-
ily explain the lack of effect of sensitivity to sCD4-17b
and sCD4 despite the strong effects on neutralizing anti-
body sensitivity. Differences in glycosylation seem an
appealing possibility for several reasons. First, the
decreased antibody sensitivity upon PBMC passage was
most dramatic for the 2G12 MAb (Fig. 5, also [30]),
whose epitope on gp120 consists of large mannose-rich
carbohydrate clusters that can be recognized by an unu-
sual domain-swapped structure of the antibody [45].
Second, gp120 is noted for its extensive “glycan shield’
that continually evolves in the infected host to sterically
block neutralizing antibodies directed against non-car-
bohydrate epitopes without affecting receptor binding
[46], since the CD4 binding site and the bridging sheet
are devoid of carbohydrate [10]. Indeed there is prece-
dence for variations in glycosylation patterns of isogenic
HIV-1 Envs dependent on the producer cell type [47].
The potent activity of sCD4-17b against PBMC-pro-
duced virions is critical, since these presumably reflect
the properties of in vivo particles more closely than do
the cell line-derived virions.
The broad, potent antiviral activity of sCD4-17b sug-
gests several possible applications. Passive immunother-
apy with MAbs has been examined both in nonhuman
primate models and human clinical trials [48], and
sCD4-17b could be considered as an additional compo-
nent to a mixture of broadly neutralizing MAbs;
however the practical limitations of passive immu-
notherapy for treating chronic HIV infection greatly
reduces enthusiasm for this mode of use. A related
alternative would involve gene therapy strategies using
either viral vectors [49] or engineered hematopoietic
stem cells [50] to continually produce sCD4-17b in the
body, for treatment or protection against HIV infection.
For such applications, it is likely that the molecule
would need to be modified for enhanced plasma half-life
by linking it to immunoglobulin constant regions, as has
been done for sCD4 [51]; indeed such a modification
might provide the additional advantage of increased
potency due to multivalent binding. Perhaps a more
likely antiviral application of sCD4-17b would be as a
topical microbicide to prevent sexual transmission. Sev-
eral classes of proteins and peptides targeting either the
virus or receptors on the host cell are being actively stu-
died for this purpose [52,53], encouraged by technolo-
gies to manufacture candidate proteins on an
economically viable scale [54]. A particularly intriguing
approach involves genetic modification of commensal
bacteria native to the healthy vaginal or rectal mucosa
to produce the anti-HIV proteins in situ [55]. For exam-
ple, vaginal strains of Lactobacillus producing CD4 in
either secreted [56] or surface-bound [57] forms have
been described; this “live microbicide” concept is being
investigated with various potent anti-HIV proteins and
peptides [58-60], and preliminary efforts have been
undertaken for sCD4-17b (L. Lagenaur and E. Berger,
unpublished). For any of the applications suggested
above, sCD4-17b has significant advantages compared to
some other candidate proteins in that it is highly speci-
fic for HIV, and is composed of entirely human-derived
sequences (except for the linkers). Thus problems asso-
ciated with immunogenicity and induction of inflamma-
tory responses are predicted to be relatively minor. We
propose that sCD4-17b warrants continued investigation
in the ongoing efforts to develop new antiviral strategies
to combat the HIV/AIDS pandemic.
Conclusions
sCD4-17b neutralizes HIV-1 with high potency and
great breadth against genetically diverse primary isolates.
It is equivalently active against virus particles generated
from different producer cell types (cell line versus
PBMC). These results support the continued investiga-
tion of various modalities by which sCD4-17b can be
employed against HIV infection.
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